Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ko Ishikawa

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Diabetes, Obesity & Metabolism|February 12, 2025
Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trialRyoichi Ishibashi, Yoko Takatsuna, Masaya Koshizaka, et al.
Journal of Diabetes Investigation|March 25, 2015
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trialHidetaka Yokoh, Kazuki Kobayashi, Yasunori Sato, et al.
Arerugi = [Allergy]|December 19, 2003
[Standard questionnaire for QOL of Japanese patients with allergic rhinitis]Minoru Okuda, Kimihiro Okubo, M Gotoh, et al.
Journal of Diabetes Investigation|August 3, 2017
Accelerated oligosaccharide absorption and altered serum metabolites during oral glucose tolerance test in young Japanese with impaired glucose toleranceTakashi Miki, Eun Young Lee, Akifumi Eguchi, et al.
Pharmacotherapy|September 29, 2023
Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reductionAyano Tsukagoshi-Yamaguchi, Masaya Koshizaka, Ryoichi Ishibashi, et al.
BMJ Open|May 12, 2017
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)Masaya Koshizaka, Ko Ishikawa, Takahiro Ishikawa, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 24, 2020
Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled StudyMasaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi, et al.
Diabetes|January 27, 2011
Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese miceXavier Prieur, Crystal Y L Mok, Vidya R Velagapudi, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 17, 2020
Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled TrialRyoichi Ishibashi, Yoko Takatsuna, Masaya Koshizaka, et al.
Heliyon|November 17, 2022
First-in-human autologous implantation of genetically modified adipocytes expressing LCAT for the treatment of familial LCAT deficiencyMasayuki Aso, Tokuo T Yamamoto, Masayuki Kuroda, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Diabetes, Obesity & Metabolism|February 12, 2025
Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trialRyoichi Ishibashi, Yoko Takatsuna, Masaya Koshizaka, et al.
Journal of Diabetes Investigation|March 25, 2015
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trialHidetaka Yokoh, Kazuki Kobayashi, Yasunori Sato, et al.
Arerugi = [Allergy]|December 19, 2003
[Standard questionnaire for QOL of Japanese patients with allergic rhinitis]Minoru Okuda, Kimihiro Okubo, M Gotoh, et al.
Journal of Diabetes Investigation|August 3, 2017
Accelerated oligosaccharide absorption and altered serum metabolites during oral glucose tolerance test in young Japanese with impaired glucose toleranceTakashi Miki, Eun Young Lee, Akifumi Eguchi, et al.
Pharmacotherapy|September 29, 2023
Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reductionAyano Tsukagoshi-Yamaguchi, Masaya Koshizaka, Ryoichi Ishibashi, et al.
BMJ Open|May 12, 2017
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)Masaya Koshizaka, Ko Ishikawa, Takahiro Ishikawa, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 24, 2020
Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled StudyMasaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi, et al.
Diabetes|January 27, 2011
Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese miceXavier Prieur, Crystal Y L Mok, Vidya R Velagapudi, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 17, 2020
Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled TrialRyoichi Ishibashi, Yoko Takatsuna, Masaya Koshizaka, et al.
Heliyon|November 17, 2022
First-in-human autologous implantation of genetically modified adipocytes expressing LCAT for the treatment of familial LCAT deficiencyMasayuki Aso, Tokuo T Yamamoto, Masayuki Kuroda, et al.
Pageof 4